Skip to main content

Table 3 Implant Utilization by Three Months (Primary Outcome) and Overall Contraceptive Use by Three Months (Secondary Outcome)

From: Primary and secondary three-month outcomes of a cluster-randomized trial of home-based postpartum contraceptive delivery in southwest Trifinio, Guatemala

 

Total Population of Women who Initiated a Method by 3 Months (n = 208)

Control Clusters [4] Women who Initiated a Method by 3 Months (n = 100, 48.1%)

Intervention Clusters [4] Women who Initiated a Method by 3 Months (n = 108, 51.9%)

P-Value

RR [95% CI]

Using a Method by 3 Months

   

< 0.001

1.3

 Yes (% of total)

139 (66.8%)

56 (56.0%)

83 (76.8%)

 

[1.1, 1.5]

Method Being Used at 3 Months

   

< 0.001

5.6

 No Method

62 (29.8%)

44 (44.0%)

18 (16.7%)

 

[2.6,12.0]

 Abstinence

0 (0.0%)

0 (0.0%)

0 (0.0%)

  

 Natural Family Planning

4 (1.9%)

1 (1.0%)

3 (2.8%)

  

 Lactational Amenorrhea

0 (0.0%)

0 (0.0%)

0 (0.0%)

  

 Condoms

1 (0.5%)

0 (0.0%)

1 (0.9%)

  

 Pills

4 (1.9%)

0 (0.0%)

4 (3.7%)

  

 Injection

99 (47.6%)

53 (53.0%)

46 (42.6%)

  

 Implant

30 (14.4%)

2 (2.0%)

28 (25.9%)

  

 Intrauterine Device

0 (0.0%)

0 (0.0%)

0 (0.0%)

  

 Female Sterilization

1 (0.5%)

0 (0.0%)

1 (0.9%)

  

 Male Sterilization

0 (0.0%)

0 (0.0%)

0 (0.0%)

  

 Missing

7 (3.4%)

0 (0.0%)

7 (6.5%)

  

Using a Short-Acting Methoda at 3 Months

   

0.72

0.98

 Yes (% of users)

104 (74.8%)

53 (94.6%)

51 (61.4%)

 

[0.8,1.1]

Using the Implant at 3 Months

   

< 0.001

1.3

 Yes (% of users)

30 (21.6%)

2 (3.6%)

28 (33.7%)

 

[1.2,1.4]

  1. Note: p-values the result of a generalized linear model mixed effects regression adjusted for cluster
  2. aShort Acting Method Includes: condoms, pills, injection